CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.01065
+0.00065 (6.50%)
At close: Aug 11, 2026

CERO Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jun '21
Net Income
-20.7-19.92-8.3-7.29-0.67-0
Depreciation & Amortization
0.270.280.440.46--
Stock-Based Compensation
3.121.960.930.1--
Other Adjustments
0.941.41-7.820.4-2.84-
Changes in Accounts Payable
1.312.270.261.281.640
Changes in Accrued Expenses
0.03-0.412.290.04--
Changes in Income Taxes Payable
----0.52-
Changes in Other Operating Activities
-1.06-1.67-0.71-0.780.25-
Operating Cash Flow
-14.4-16.08-12.92-5.79-1.090
Operating Cash Flow Growth
------
Purchases of Investments
-----0.33-
Proceeds from Sale of Investments
-0.5--181.16-
Investing Cash Flow
-0.5--180.84-
Short-Term Debt Issued
--0.41---
Short-Term Debt Repaid
---0.4---
Net Short-Term Debt Issued (Repaid)
--0.01---
Long-Term Debt Issued
--0.010.610.65-
Long-Term Debt Repaid
---0.02---
Net Long-Term Debt Issued (Repaid)
---0.010.610.65-
Issuance of Common Stock
4.389.434.810.01--
Repurchase of Common Stock
-----139.35-
Net Common Stock Issued (Repurchased)
4.389.434.810.01-139.35-
Issuance of Preferred Stock
-4.998.92---
Repurchase of Preferred Stock
--0.4----
Net Preferred Stock Issued (Repurchased)
-4.598.92---
Other Financing Activities
--0.11--0.04--
Financing Cash Flow
9.5513.9213.730.57-138.7-
Net Cash Flow
-4.35-1.660.81-5.2241.040
Free Cash Flow
-14.4-16.08-12.92-5.79-1.090
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.27-3.80-445.81--98.14-
Levered Free Cash Flow
-89.52-95.06-8.81-5.682.390
Unlevered Free Cash Flow
-17.81-17.99-13.92-6.6747.370